Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher-Life Tech Deal Clears EC Hurdle

NEW YORK (GenomeWeb News) – The European Commission has approved Thermo Fisher Scientific's $13.6 billion purchase of Life Technologies, Thermo Fisher said today.

Thermo Fisher will sell its cell culture, gene modulation, and magnetic beads business in order to expedite the approval, it said, adding that the businesses to be divested had combined revenues of $225 million in 2012.

Goldman Sachs analyst Isaac Ro said in a note today that the three businesses comprised less than 2 percent of Thermo Fisher's total revenues.

"[W]e do not believe these businesses were significant contributors to organic growth, and do not see these requirements as altering the strategic appeal of the proposed transaction," he said.

The brands to be sold as part of the divestiture include HyClone, Dharmacon, Open Biosystems, and Sera-Mag, and potential buyers for the businesses could include Bio-Rad Laboratories, Merck KGaA, Sigma-Aldrich, and Techne, ISI Group's Ross Muken said.

The deal still needs to be approved by the US Federal Trade Commission, as well as Chinese regulators. Based on discussions with FTC, Thermo Fisher said that it does not believe it will need to divest additional businesses in order to gain approval with the agency. The deal is anticipated to close in early 2014.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.